Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) issued its earnings results on Thursday. Here are the key takeaways from Trevi Therapeutics’ conference call:Get Trevi Therapeutics alerts:Clinical programs remain on track: Trevi initiated the OCEAN-1 Phase III IPF-related chronic cough trial and LAKE-2b Phase II trial in refractory chronic cough during Q2, with OCEAN-2 planned for Q3. Trevi initiated the OCEAN-1 Phase III IPF-related chronic cough trial and LAKE-2b Phase II trial in refractory chronic cough during Q2, with OCEAN-2 planned for Q3. Trevi Therapeutics Stock Up 0.1%NASDAQ TRVI traded up $0.01 on Friday, reaching $18.51. Featured StoriesReceive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.